Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2024
0mins
Should l Buy ?
Source: Yahoo Finance
- Acquisition Deal: Japanese pharma company ONO Pharmaceutical to acquire Deciphera Pharmaceuticals Inc for $2.4 billion.
- Deciphera's Offerings: Deciphera brings kinase drug discovery capabilities, commercial platforms in the U.S. and Europe, and a pipeline of cancer drugs.
- Premium Price: The acquisition price of $25.60 per share represents a premium of 74.7% to Deciphera's closing share price on April 26, 2024.
- Expected Closure: The acquisition is set to close in the third quarter of 2024, with Deciphera operating as a standalone business under ONO Group.
- Stock Performance: Deciphera Pharmaceuticals' stock (DCPH) surged by 75.01% to $25.21 following the acquisition news.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
